Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
| ▸ | CCL2 | P13500 | 1/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11068277 | 0.75 | BRD4 (0.35) | BRD4CCL2HTR2AATM | |
| SCHEMBL418352 | 0.68 | BRD4 (0.38) | BRD4CCL2HTR2AATM | |
| SCHEMBL11611849 | 0.67 | ATM (0.34) | BRD4CCL2ATM | |
| SCHEMBL11348748 | 0.64 | BRD4 (0.41) | BRD4CCL2HTR2AATM | |
| SCHEMBL25038692 | 0.63 | BRD4 (0.36) | BRD4CCL2HTR2A | |
| SCHEMBL17284105 | 0.62 | BRD4 (0.36) | BRD4CCL2HTR2AATM | |
| SCHEMBL10870805 | 0.61 | ATM (0.37) | BRD4CCL2ATM | |
| SCHEMBL8003375 | 0.61 | BRD4 (0.35) | BRD4CCL2HTR2AATM | |
| Hydrochloric Acid SCHEMBL11111763 | 0.61 | BRD4 (0.35) | BRD4CCL2HTR2AATM | |
| SCHEMBL514156 | 0.61 | BRD4 (0.34) | BRD4CCL2HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240199609-A1 | COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF SHP2 | NOVARTIS AG (CH) | 2024-06-20 | — | — | US | disclosed |
| US-11905283-B2 | Compounds and compositions for inhibiting the activity of SHP2 | NOVARTIS AG (CH) | 2024-02-20 | — | — | US | disclosed |
| EP-0166439-B1 | 4H-pyrimido[2,1-a]isoquinolin-4-one derivatives | G.D. Searle & Co. (US) | 1990-05-09 | — | — | EP | disclosed |
| US-4661592-A | ANORECTIC AGENTS | G. D. SEARLE & CO. (US) | 1987-04-28 | — | — | US | disclosed |
| EP-0166439-A2 | 4H-pyrimido[2,1-a]isoquinolin-4-one derivatives | G.D. Searle & Co. (US) | 1986-01-02 | — | — | EP | disclosed |
| US-4535081-A | Antiallergic and antiulcer 1-oxo-1H-thiazolo[3,2-a]pyrimidine-2-carboxamides and intermediates therefor | PFIZER INC. (US) | 1985-08-13 | — | — | US | disclosed |
| US-4423048-A | Antiallergic and antiulcer 1-oxo-1H-thiazolo[3,2-a]pyrimidine-2-carboxamides and intermediates therefor | PFIZER INC. (US) | 1983-12-27 | — | — | US | disclosed |
| US-4414388-A | ANTIALLERGENS, ANTIULCER AGENTS | PFIZER INC. (US) | 1983-11-08 | — | — | US | disclosed |
| US-4127720-A | ANTIALLERGENS | BRISTOL-MYERS COMPANY (US) | 1978-11-28 | — | — | US | disclosed |
| US-4127720-A | ANTIALLERGENS | BRISTOL-MYERS COMPANY (US) | 1978-11-28 | — | — | US | disclosed |
| US-4127720-A | ANTIALLERGENS | BRISTOL-MYERS COMPANY (US) | 1978-11-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11905283-B2 | Compounds and compositions for inhibiting the activity of SHP2 | PTPN1, PTPN2, PTPN5 | BRD4 1319/4885CCL2 255/4885HTR2A 3903/4885 |
| US-20240199609-A1 | COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF SHP2 | PTPN1, PTPN2, PTPN5 | BRD4 1319/4885CCL2 255/4885HTR2A 3903/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.